Bill on seat belt admissibility heads to Governor
Gustavsen v. Alcon
(1st Circ., filed April 11, 2018): Arguing that the plaintiffs’ speculative claim that they might have paid less for a medication if defendants had packaged it more efficiently does not describe a cognizable injury in fact, and therefore, they lack standing. Accepting plaintiffs’ theory would invite abusive class-action litigation.
On August 27, 2018, the court held that defendants could not change the drop size of an FDA-approved drug without prior FDA approval and thus that plaintiffs’ state-law claims were preempted.
SCOTUS Determining Whether to Hear Appeal by Defendant
Writing for The Hill, ATRA President Tiger Joyce discusses the Biden administration’s plans to allow a settlement slush fund and issues the practice has caused at the state level.
ATRA President Tiger Joyce writes about issues with a landmark talc case in Missouri and how the U.S. Supreme Court can step in.
Trial lawyers’ spending on covid ads last year surpassed $260,000